CARB-X Funds VenatoRx to Support Development of New Class of Oral Antibiotics to Treat Multi-Drug-Resistant Gonorrhoea

Kevin Outterson and CARB-X featured in article “CARB-X Funds VenatoRx to Support Development of New Class of Oral Antibiotics to Treat Multi-Drug-Resistant Gonorrhoea”, Pharmaceutical Business Review.